Search results
Moderna (NASDAQ:MRNA) PT Raised to $106.00
ETF DAILY NEWS· 8 hours agoModerna (NASDAQ:MRNA – Free Report) had its price target increased by Canaccord Genuity Group from $91.00 to $106.00 in a report published on Friday, Benzinga reports. Canaccord ...
Tech Bytes: Moderna partners with OpenAI to expedite drug development processes
Proactive Investors· 4 hours agoModerna, the biotechnology firm best known for its COVID-19 vaccines, has partnered with artificial...
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 5 days agoModerna (MRNA) delivered earnings and revenue surprises of 14.48% and 33.88%, respectively, for the...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 4 days agoModerna experienced a substantial financial shift in the first quarter (Q1) of 2024, reporting a net loss of $1.2bn - a stark contrast to its net income...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via AOL· 5 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Earnings call: Moderna reports a net loss of $12.2 billion By Investing.com
Investing.com· 5 days agoModerna , Inc. (NASDAQ:MRNA) reported a mixed first quarter in 2024, with significant business...
Unveiling Moderna (MRNA)'s Value: Is It Really Priced Right? A C
Guru Focus· 19 hours agoToday, Moderna Inc (MRNA, Financial) experienced a stock price decline of 3.43%, yet it has seen a significant three-month gain of 28.21%. With a current Loss Per Share standing ...
Moderna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Barrons.com· 5 days agoModerna reported first-quarter financial results Thursday that soundly beat Wall Street...
Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?
Investor's Business Daily· 5 days agoModerna (MRNA) beat Wall Street's first-quarter expectations Thursday. The Covid vaccine maker came...
Moderna's Options Frenzy: What You Need to Know - Moderna (NASDAQ:MRNA)
Benzinga· 20 hours agoLoading... Loading... Deep-pocketed investors have adopted a bullish approach towards Moderna MRNA , and it's something market players shouldn't ignore. Our tracking of public ...
